Two drugstore chains are alleging in federal court that Wyeth Inc., owner of the patent on the antidepressant Effexor XR, conspired illegally with another drug maker to delay introduction of a generic substitute.
The plaintiffs, in Rite Aid Corp. v. Wyeth Inc., 12-cv-3523, filed Tuesday, allege that although Wyeth’s patent for Effexor XR ran out in June 2008, it kept Teva Pharmaceuticals USA’s lower-cost version off the market until July 2010.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
